Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences.
Citi BioPharma Conference
Date: Wednesday, September 6 – Thursday, September 7, 2023
Location: Four Seasons, Boston, MA
Baird Global Healthcare Conference
Date: Tuesday, September 12 – Wednesday, September 13, 2023
Location: InterContinental New York Barclay, New York, NY
Leerink Partners Biopharma Summit
Date: Wednesday, September 20 – Friday, September 22, 2023
Location: Rosewood Miramar Beach, Montecito, CA
Cantor Global Healthcare Conference
Date: Tuesday, September 26 – Thursday, September 28, 2023
Location: InterContinental New York Barclay, New York, NY
Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler
Investor Relations
dspangler@reneopharma.com
Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
matthew.purcell@russopartnersllc.com


The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.